Levi & Korsinsky announces it has commenced an investigation of BioCryst Pharmaceuticals, Inc. (NASDAQGS: BCRX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.

On February 8, 2016, BioCryst Pharmaceuticals announced disappointing results for its OPuS-2 clinical trial of avoralstat. Following this news, BioCryst Pharmaceuticals stock was down as much as 67% on February 8, 2016. To obtain additional information, go to:

http://zlk.9nl.com/biocryst-pharmaceuticals-bcrx

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208006030/en/

Copyright Business Wire 2010